The main purpose of this legislation, known as the Prescription Pricing for the People Act of 2025, is to require the Federal Trade Commission (FTC) to investigate the role of intermediaries in the pharmaceutical supply chain. The goal is to understand how these intermediaries, such as pharmacy benefit managers, affect drug pricing and competition, and to provide Congress with recommendations for improving the situation. Key provisions of the legislation include a mandate for the FTC to produce a comprehensive report within one year of the law's enactment.